361-375 of 837
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Oncology and HematologyTAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyUpdates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyTAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Oncology and HematologyPhase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Oncology and HematologyUpdates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Oncology and HematologyReal-World Sequencing and Survival in Locally Advanced Prostate Cancer
- advertisement
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Oncology and HematologyEvolving Trends in Germline Genetic Testing for Prostate Cancer
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Project Oncology®Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms
DermConsultCannabis Extract and Melanoma: Insights into Cell Death Mechanisms
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
Project Oncology®mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
Project Oncology®Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
- advertisement
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Project Oncology®Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Project Oncology®Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
The Necessity of a Multidisciplinary Approach Through the mCRPC Treatment Journey
Project Oncology®The Necessity of a Multidisciplinary Approach Through the mCRPC Treatment Journey
